Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil

Memorias do Instituto Oswaldo Cruz

Volumn 99, Issue 8, 2004, Pages 877-882

  Cerqueira, Daniela M ^a,d   Amorim, Regina M S ^a   Silva, Ruiter R ^b   Camara, Geni N L ^c   Brígido, Marcelo M ^a   Martins, Cláudia R F ^a  

^a Instituto de Biologia   (Brazil)

^b Lab Ctrl Saude Pub do Distrito F   (Brazil)

^c Agencia Nacional de Vigilancia Sanitaria Brazil   (Brazil)

^d Fellow of the National Research Council   (Brazil)

Author keywords

Antiretroviral resistance; Brazil; Genotyping; Human immunodeficiency virus type 1 (HIV 1); Protease; Reverse transcriptase

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS ENZYME; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BRAZIL; CODON; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHYLOGENY; PREVALENCE; TREATMENT FAILURE; VIRUS GENE; VIRUS ISOLATION; VIRUS TYPING;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 13844297834     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762004000800016     Document Type: Article

References (30)

1. Brasil 1999. Ministério da Saúde, Coordenação Nacional de DST e AIDS, Projeto piloto de monitoramento da resistência do HIV-1 aos anti-retrovirais. Apostila e protocolos do curso de genotipagem rápida do HIV-1.
2. Brenner B, Wainberg MA, Salomon H, Rouleau D, Dascal A, Spira B, Sekaly R-P, Conway B, Routy J-P, Investigators of the Quebec Primary Infection Study 2000. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Int J Antimicrob Agents 16: 429-434.
3. Brindeiro PA, Brindeiro RM, Mortensen C, Hertogs K, De Vroey V, Rubini NP, Sion FS, De Sa CA, Machado DM, Succi RC, Tanuri A 2002. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J Clin Microbiol 40: 4512-4519.
4. Cerqueira DM, Ramalho ED, Oliveira CP, Silva RR, Franchini M, Felipe MSS, Martins CRF 2004. HIV-1 subtypes and mutations associated to antiretroviral drug resistance in human isolates from Central Brazil. Braz J Microbiol 35, accepted.
5. Dumans AT, Soares MA, Pieniazek D, Kalish ML, De Vroey V, Hertogs K, Tanuri A 2002. Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil. Antimicrob Agents Chemother 46: 3075-3079.
6. Felsenstein J 1993. PHYLIP (Phylogeny Inference Package) version 3.5c. Distributed by the author. Department of Genetics, University of Washington, Seattle.
7. Gadelha SR, Shindo N, Cruz JNM, Morgado MG, Galvão-Castro B 2003. Molecular epidemiology of human immunodeficiency virus-1 in the state of Ceará, Northeast, Brazil. Mem Inst Oswaldo Cruz 98: 461-464.
8. Gonzales MJ, Machekano RN, Shafer RW 2001. Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a Northern California clinic-based population. J Infect Dis 184: 998-1006.
9. Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kruitzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 37: 113-28.
10. Holguín A, Álvarez A, Soriano V 2002. High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS 16: 1163-1170.
11. Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD, International AIDS Society-USA Drug Resistance Mutations Group 2003. Drug resistance mutations in HIV-1. Topics in HIV Medicine 11: 215-221.
12. Little SJ, Holte S, Routy J-P, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347: 385-394.
13. Kimura M 1980. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequence. J Mol Evol 16: 111-120.
14. Magiorkinis E, Paraskevis D, Magiorkinis G, Chryssou S, Chini M, Lazanas M, Paparizos V, Saroglou G, Antoniadou A, Giamarellou E, Karafoulidou A, Hatzakis A 2002. Mutations associated with genotypic resistance to antiretroviral therapy in treatment naïve HIV-1 infected patients in Greece. Virus Res 85: 109-115.
15. Morgado MG, Guimarães ML, Galvão-Castro B 2002. HIV-1 polymorphism: a challenge for vaccine development - A review. Mem Inst Oswaldo Cruz 97: 143-150.
16. Njouom R, Pasquier C, Sandres-Sauné K, Harter A, Souyris C, Izopet J 2003. Assessment of HIV-1 subtyping for Cameroon strains using phylogenetic analysis of pol gene sequences. J Virol Meth 110: 1-8.
17. Pasquier C, Millot N, Njouom R, Sandres K, Cazabat M, Puel J, Izopet J 2001. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. 2001. J Virol Meth 94: 45-54.
18. Perrin L, Kaiser L, Yerly S 2003. Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis 3: 22-27.
19. Rambaut A, Posada D, Crandall KA, Holmes EC 2004. The causes and consequences of HIV evolution. Nature Reviews 5: 52-61.
20. Ramos A, Tanuri A, Schechter M, Rayfield MA, Hu DJ, Cabral MC, Bandea CI, Baggs J, Pieniazek D 1999. Dual and recombinant infections: an integral part of the HIV-1 epidemic in Brazil. Emerg Infect Dis 5: 65-74.
21. Ray SC 1999. SimPlot for Windows (version 2.5). Baltimore, MD. Distributed by author. Available at http://sray.med.som.jhmi.edu/RaySoft/ SimPlot/.
22. Rhee S-Y, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW 2003. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31: 298-303.
23. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish ML, Kuiken C, Learn GH, Leitner T, McCutchan F, Osmanov S, Peeters M, Pieniazek D, Salminen M, Sharp PM, Wolinsky S, Korber B 1999. HIV-1 nomenclature proposal. In CL Kuiken, B Foley, B Hahn, B Korber, F McCutchan, PA Marx, JW Mellors, JI Mullins, J Sodroski, S Wolinksy 1999. Human Retroviruses and AIDS 1999: a Compilation and Analysis of Nucleic Acid and Amino Acid Sequences, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, p. 492-505.
24. Rossini MAA, Diaz RS, Caseiro M, Turcato G, Accetturi CA, Sabino EC 2001. HIV-1 subtypes among intravenous drug users from two neighboring cities in São Paulo State, Brazil. Braz J Med Biol Res 34: 45-47.
25. Shafer RW 2002. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 15: 247-277.
26. Shafer RW 2003. Genotypic testing for HIV-1 drug resistance. Available at http://hivdb.stanford.edu.
27. Soares EAJM, Santos RP, Pellegrini JA, Sprinz E, Tanuri A, Soares MA 2003. Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in Southern Brazil. J AIDS 34: 520-526.
28. Tanuri A, Caridea E, Dantas MC, Morgado MG, Mello DL, Borges S, Tavares M, Ferreira SB, Santoro-Lopes G, Martins CR, Esteves AL, Diaz RS, Andreo SM, Ferreira LA, Rodrigues R, Reuter T, Cavalcanti AM, de Oliveira SM, de Barbosa HB, Teixeira PR, Chequer PN 2002. Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART. J Clin Virol 25: 39-46.
29. Thompson J, Higgins D, Gibson T 1994. CUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acid Res 22: 4673-4680.
30. Thomson MM, Pérez-Álvarez L, Nájera R 2002. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2: 461-471.